Comparative Pharmacology
Head-to-head clinical analysis: DIFLORASONE DIACETATE versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLORASONE DIACETATE versus POKONZA.
DIFLORASONE DIACETATE vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflorasone diacetate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby controlling the biosynthesis of potent mediators of inflammation like prostaglandins and leukotrienes.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Apply a thin film to affected skin areas twice daily (every 12 hours). Use the lowest effective strength and duration.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal elimination half-life of approximately 5.7 hours (range 4.4–7.1 h) after topical application; prolonged in hepatic impairment.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Primarily renal (≤5% unchanged); extensive hepatic metabolism with biliary/fecal elimination of metabolites; total recovery: ~60% in urine (metabolites), ~30% in feces.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid